Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
暂无分享,去创建一个
A. Bass | W. Park | T. Sohn | J. Bae | W. Kang | R. Lanman | K. Banks | J. Lee | S. Kim | Amirali Talasaz | H. Lim | S. Park | K. Kim | E. Pectasides | J. Park | Y. Park | S. Kim | J. Lee | J. An | M. Choi | N. Kim | H. Lee
[1] Y. Bang,et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Joon-Oh Park,et al. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib , 2016, Molecular Cancer Therapeutics.
[3] S. Bosari,et al. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists , 2016, World journal of gastroenterology.
[4] Joon-Oh Park,et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Sue Chua,et al. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. , 2016, Cancer discovery.
[6] G. Lee,et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). , 2016, European journal of cancer.
[7] Joon-Oh Park,et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients , 2015, Oncotarget.
[8] Jeffrey W. Clark,et al. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. , 2015, Cancer discovery.
[9] Jason G. Jin,et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.
[10] Kyoung-Mee Kim,et al. The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer , 2015, Scientific Reports.
[11] A. Bass,et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. , 2014, The Journal of clinical investigation.
[12] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[13] Y. Bang,et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Hidalgo,et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Joon-Oh Park,et al. A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers , 2013, PloS one.
[16] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[17] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[18] Yoon-Koo Kang,et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.